{"subject": "CHEBI:68579", "predicate": "biolink:contributes_to", "object": "MONDO:0002251", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:5156547", "PMC:2730547", "PMC:5003057"], "tmkp_confidence_score": 0.6128887859621844, "sentences": "Aside from bleeding, some of the additional side effects of rivaroxaban include the following: dizziness (6%), peripheral edema (6%), hypersensitivity reactions or rash (2%), syncope (2%), and though more rare, thrombocytopenia, agranulocytosis, hepatitis, pruritis, and Stevens?Johnson syndrome.|NA|In the third patient, rivaroxaban was stopped after 23 d, when hepatitis B with seroconversion was diagnosed; the patient died of acute liver failure, mostly due to fatal hepatitis B infection, 48 d after starting treatment.|NA|Non-hemorrhagic adverse effects of rivaroxaban in the EINSTEIN-EXT study were upper abdominal pain, dyspepsia, sinusitis, tooth ache, UTI, back pain and fatigue (all less than 5%) whereas post marketing voluntary reporting of adverse effects include anaphylaxis, angioedema, Stevens-Johnson syndrome, agranulocytosis, jaundice and hepatitis.|NA", "tmkp_ids": ["tmkp:21709dfe811f66a9f620d41080651d41e3d1d379af32db099f3d5a7b494bb6cb", "tmkp:fd2d3e43f75ceac886f3de1b65395369865a1648efc1371ea27bc5b724668584", "tmkp:a62f721434da7ccccc0aee9c2709dc7e571c1caea24237d2ce5dee0cb76a9958"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB06228", "original_object": "MONDO:0002251"}
{"subject": "CHEBI:3387", "predicate": "biolink:affects", "object": "UniProtKB:P35523", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMID:32593548"], "tmkp_confidence_score": 0.99969363, "sentences": "Carbamazepine reduced myotonia in eight treated patients.|NA", "tmkp_ids": ["tmkp:280d88c8c29f7338bd88c0b2fc06d0433e1503c4e9163d185fc0ce4a7bb31bb8"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "decreased", "original_subject": "DRUGBANK:DB00564", "original_object": "UniProtKB:P35523"}
{"subject": "UniProtKB:O94808", "predicate": "biolink:affects", "object": "UniProtKB:Q15349", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6978753"], "tmkp_confidence_score": 0.99060655, "sentences": "CDH1, Cadherin 1; NES-1, Normal epithelial cell-specific 1; DKK-3, Dickkopf WNT signaling pathway inhibitor 3; CDH13, Cadherin 13, TMS1, Target of methylation induced silencing; DAPK, Death-associated protein kinase; LATS1, Large tumor suppressor kinase 1; PTEN; Phosphatase and tensin homolog; CALC1, Calcitonin; LATS2, Large tumor suppressor 2; GIPC2, GIPC PDZ domain containing family member 2; RSPO1, R-spondin 1; MAGI1, Membrane associated guanylate kinase, WW and PDZ domain-containing protein 1; CAST1, Cytosolic arginine sensor for MTORC1 subunit 1; ADCY5, Adenylate cyclase 5; HSPA4L, Heat shock protein family A (Hsp70) member 4 Like; OCLN, Occludin; EFNA5, Ephrin A5; MSX2, Msh homeobox 2; GFPT2, Glutamine-fructose-6-phosphate transaminase 2; GNA14, G protein subunit alpha 14; SALL1, Spalt like transcription factor 1; MYO5B, Myosin VB; ZNF382, Zinc finger protein 382; MN1, Meningioma 1; PLK2, Polo-like kinase 2; CDKN2A, Cyclin-dependent kinase Inhibitor 2A; PTPRO, Protein tyrosine phosphatase receptor-type O; NOTCH4, Notch receptor 4; TOP1MT, Topoisomerase (DNA) I, mitochondrial; HOXA4, Homeobox A4; TAL1, TAL BHLH transcription factor 1; MEIS1, Meis homeobox 1; PLK1, Polo-like kinase 1; ABCA2, ATP binding cassette subfamily A member 2; ABCA3, ATP binding cassette subfamily A member 3; CLUS, Clusterin; CERU, Ceruloplasmin; FCN3, Ficolin 3; APOA1, Apolipoprotein A1; APOE, Apolipoprotein E; APOA4, Apolipoprotein A4; ACTB, Actin beta; CATA, Catalase; AFAM, Afamin; AMBP, Alpha-1-microglobulin/bikunin precursor; GELS, Gelsolin; S10A9, S100 calcium binding protein A9 gene; PARP, Poly [ADP-ribose] polymerase 1; PDK, Pyruvate dehydrogenase kinase; PKAc, cAMP-dependent protein kinase catalytic subunit; p90RSK, 90 kDa ribosomal s6 kinase; IKBA, Ikappabalpha; GRB2, Growth factor receptor bound protein 2; YY1, Yin Yang 1; MDR1, Multi-drug resistance-1.|NA", "tmkp_ids": ["tmkp:e4fe2ceb235958dd8b6b53fc5bf154767debf0ba75d71b19a022a576bc316f55"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "decreased", "original_subject": "UniProtKB:O94808", "original_object": "UniProtKB:Q15349"}
{"subject": "CHEBI:17833", "predicate": "biolink:contributes_to", "object": "HP:0002153", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:4458901"], "tmkp_confidence_score": 0.7844641251799579, "sentences": "Hyperkalemia produced due to GM was normalized in BA treated group substantiating its protective effect and was statistically significant.|NA", "tmkp_ids": ["tmkp:ad05984693525a034f7444d7d21418117b9a87c9fea96e2fc4c2bc584449c4ac"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00798", "original_object": "HP:0002153"}
{"subject": "HP:0000682", "predicate": "biolink:subclass_of", "object": "HP:0000118", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "HP:0000682", "original_object": "HP:0000118"}
{"subject": "UMLS:C1709028", "predicate": "biolink:subclass_of", "object": "MONDO:0006456", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "NCIT:C45708", "original_object": "NCIT:C3411"}
{"subject": "CHEBI:32374", "predicate": "biolink:subclass_of", "object": "CHEBI:33285", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:32374", "original_object": "CHEBI:33285"}
{"subject": "MONDO:0001244", "predicate": "biolink:subclass_of", "object": "HP:0032245", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "HP:0011892", "original_object": "HP:0032245"}
{"subject": "CHEBI:41500", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0008322", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6168010"], "tmkp_confidence_score": 1.044830170792626, "sentences": "Our first therapeutic approach to treat PSACH in our MT-COMP mouse was administration of ER stress reducing, drugs valproate, lithium and phenylbutyric acid from birth until 4 weeks after birth.|NA", "tmkp_ids": ["tmkp:a8823fbb4e8b65e6e3c7935dbbeec975cbcdf00af0948ee62768e31464156d40"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB06819", "original_object": "MONDO:0008322"}
{"subject": "CHEBI:185729", "predicate": "biolink:subclass_of", "object": "CHEBI:22727", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:185729", "original_object": "CHEBI:22727"}
{"subject": "CHEBI:31355", "predicate": "biolink:affects", "object": "UniProtKB:Q00987", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMID:26494859"], "tmkp_confidence_score": 0.99948406, "sentences": "In mutant p53 TMD231 TNBC cells, carboplatin and Nutlin-3a led to increased Mdm2 and was strongly synergistic in promoting cell death in vitro.|NA", "tmkp_ids": ["tmkp:5e313b6e7590d889e2219fe7040fddcfe26b869d5f608a6b25d1a1a04722f94c"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "increased", "original_subject": "DRUGBANK:DB00958", "original_object": "UniProtKB:Q00987"}
{"subject": "CHEBI:3438", "predicate": "biolink:subclass_of", "object": "CHEBI:51069", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:3438", "original_object": "CHEBI:51069"}
{"subject": "PR:000037681", "predicate": "biolink:subclass_of", "object": "UniProtKB:P49768", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "PR:000037681", "original_object": "PR:P49768"}
{"subject": "UMLS:C0593103", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0019312", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:2291310"], "tmkp_confidence_score": 0.9275679898559188, "sentences": "Since then there have been a large number of reports on efficacy of rFVIIa in GT as well as other platelet function disorders including Bernard Soulier Syndrome; platelet storage pool defect including Hermansky-Pudlak syndrome, and platelet-type (pseudo) von Willebrand disease.|NA", "tmkp_ids": ["tmkp:b19b2f7a05b1c0a3a12e4d054bbd562caac8a7a9c7d813269f8ce6438f1b27c3"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00036", "original_object": "MONDO:0019312"}
{"subject": "CHEBI:36009", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0005267", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9113147", "PMC:4431415"], "tmkp_confidence_score": 0.5388464144180738, "sentences": "Some oils are also nutritionally important due to their requirement in a healthy diet including long-chain omega-3 and omega-6 fatty acids which have functions that help prevent heart disease and stroke (R?os-Covi?n et al.,).|NA|Furthermore, EPUFAs such as omega-3 and omega-6 fatty acids have important effects on the body, particularly relevant to enhancing appropriate pre- and postnatal development (mainly of the central and peripheral nervous systems), lowering cholesterol and triglyceride levels, reducing acute and chronic inflammation, treating patients with neurodegenerative disorders, contributing to blood pressure regulation, and reducing the odds of developing cancer, heart disease, and stroke.|NA", "tmkp_ids": ["tmkp:37dfbae222f18b02ab7dbcef8a1e2e484d06b585634ad7e8aa9bea767d72670f", "tmkp:b60a7e5818bb5934267b44b245e3c129299efee36a60f966a07c15c1eceaf367"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB13168", "original_object": "MONDO:0005267"}
{"subject": "UniProtKB:P15692", "predicate": "biolink:subclass_of", "object": "CHEBI:33579", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "PR:P15692", "original_object": "CHEBI:33579"}
{"subject": "CHEBI:9765", "predicate": "biolink:affects", "object": "UniProtKB:P28324", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMID:23619703"], "tmkp_confidence_score": 0.999678, "sentences": "Interestingly SAP-1 also inhibits the activity of trypsin, chymotrypsin, pepsin, and PSA (prostate specific antigen) and acts as a cross-class protease inhibitor in in?vitro studies.|NA", "tmkp_ids": ["tmkp:c470466459d2517b4e22602328046ad8c5909d1112a0e5ead82fcf81f7fb1013"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "decreased", "original_subject": "DRUGBANK:DB11237", "original_object": "UniProtKB:P28324"}
{"subject": "CHEBI:3207", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0002783", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7708268", "PMC:7708268", "PMC:7708268"], "tmkp_confidence_score": 0.9865026, "sentences": "Budesonide/formoterol significantly reduces the frequency of these events versus formoterol alone, without an associated increase in the rate of LRTI and pneumonia.|NA|Finally, we assess whether therapy with budesonide/formoterol versus formoterol alone can reduce the frequency of, and outcomes associated with, COPD symptom-related attacks, and whether this addition of an inhaled corticosteroid (ICS) to a long-acting ?2-agonist (LABA) is associated with an increased incidence of lower respiratory tract infections (LRTI) and pneumonia.|NA|In addition to highlighting the incidence and importance of COPD symptom-related attacks, our analysis also showed that adding budesonide to formoterol significantly reduces the frequency of these attacks versus formoterol alone, without the increased risk of LRTI or pneumonia.|NA", "tmkp_ids": ["tmkp:8a00e41fc8ab25edc0b73ee2df14171a9a85d036a97261e177e600e8c936111c", "tmkp:63ffc9358890913b843d836527a07b7f8bb7f8112483f4184271ea6dec6b7444", "tmkp:02732dba589fa52d1e62ebfe15ab2ce76860307bd5e97a1287347fc86611ab98"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB01222", "original_object": "HP:0002783"}
{"subject": "UNII:15C2VL427D", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0005015", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7574888", "PMC:7574888", "PMC:7574888", "PMC:7574888", "PMC:7536789"], "tmkp_confidence_score": 0.6051366468624383, "sentences": "Here, using an STZ-induced murine model of diabetes, we examined the protective effects of aflibercept against microvascular structural changes that occur in the early stage of DR, such as pericyte loss, hyperpermeability, perfusion blockage, and inflammation.|NA|Leukocyte recruitment in the retinal periphery was also lower in aflibercept-treated mice with diabetes compared with that in control mice with diabetes without aflibercept treatment (figure 4C, D).|NA|Using the STZ model of diabetes, we found that aflibercept, a potent anti-VEGF molecular trap, is highly effective in reducing these microvascular structural changes in DR.|NA|Aflibercept treatment ameliorates retinal hypoperfusion and reduces leukocyte recruitment in mice with diabetes.|NA|In the PERMEATE study, a prospective study that included 29 treatment na?ve eyes with macular edema due to DM (14 eyes) or retinal vein occlusion (15 eyes), patients received aflibercept injections every 4 weeks for the first 6 months followed by every 8 weeks for the next 6 months with specific rescue criteria to return to every 4 weeks dosing and were followed up with ultra-widefield fluorescein angiography.|NA", "tmkp_ids": ["tmkp:3821582b4840a231bf4687cc909d3deedb732551c5e31b2f8b140ab5d4b8d9d8", "tmkp:a616d13e4e7ea6d8817e5a951295eb691947c614b0d86ee1fe8c3717f5efac67", "tmkp:f208fc333ee12a906869fdc46d76bd38ecf6a0e9a04e7f2377ad25facca426a5", "tmkp:ca6b71d46b7028c164c1c4673fc15dab688ce5f662106277fcc70fdceb38f895", "tmkp:20101be121d1277e49c22fcfc6ebaada2154d20dffa3d5d0836c10e770e87bea"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB08885", "original_object": "MONDO:0005015"}
{"subject": "CHEBI:37290", "predicate": "biolink:subclass_of", "object": "CHEBI:18367", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:37290", "original_object": "CHEBI:26020"}
{"subject": "HP:0033533", "predicate": "biolink:subclass_of", "object": "MONDO:0004995", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "HP:0033533", "original_object": "HP:0001626"}
{"subject": "CHEBI:68478", "predicate": "biolink:contributes_to", "object": "HP:0001410", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6624115", "PMC:6624115"], "tmkp_confidence_score": 1.1223442461814646, "sentences": "After treatment, the rhabdomyomas shrank rapidly, but the serum concentration of everolimus increased sharply (maximum serum trough level: 76.1 ng/mL) and induced complications including pulmonary hemorrhage, liver dysfunction, and acne.|NA|The high serum trough level of everolimus may be related to the pulmonary hemorrhage, acne, and liver dysfunction seen in this patient.|NA", "tmkp_ids": ["tmkp:768e3232a2c4470b1ca3d5f65526229f4bd1525f0791893d2423994dc5942742", "tmkp:e3c02ada0c20ae811681422824206980c0eabadb70d99953d95fb1c408c30927"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB01590", "original_object": "HP:0001410"}
{"subject": "UMLS:C0085295", "predicate": "biolink:contributes_to", "object": "MONDO:0002714", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:3270544"], "tmkp_confidence_score": 0.6055379097071585, "sentences": "IL10 promotes CNS tumor growth and migration, whereas TGF-? is an important regulator of tumorigenesis, angiogenesis, and tumor cell motility and invasiveness.|NA", "tmkp_ids": ["tmkp:9a60862a3460db3eb38abcbce428e7049955d37b60882bb1e6837b33e6640f57"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB12880", "original_object": "MONDO:0002714"}
{"subject": "CHEBI:25681", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0040270", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:4886737", "PMC:5067287", "PMC:2705820", "PMC:6522756"], "tmkp_confidence_score": 0.9020263, "sentences": "The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial was the first large study to investigate the efficacy of long-term omega-3 fatty acid supplementation on cardiovascular events in individuals with CVD plus impaired glucose tolerance, impaired fasting glucose, or diabetes.|NA", "tmkp_ids": ["tmkp:cbb1f03888ef223807cf0d6356cbde9d401e119a3c9e518997c2d20d3f6bcfe1", "tmkp:ef2128a46b6b423549013e1484638bf27648f58b7313e8e42fb4d2aebfed4370", "tmkp:bd2736b9453a799e77b82f2057c75b43eca3eb81c67a9acaebbf06b894ce322e", "tmkp:9d3af4e05f503a5ad6cce5c334cc7694722ff97aaf76cf81c4f234ac3b7dcf9b", "tmkp:809b7db9c7b7a0570e149645e1b016f3ec283a52dde3109e13574152b6dc0d51"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "CHEBI:25681", "original_object": "HP:0040270"}
{"subject": "UNII:DPT0O3T46P", "predicate": "biolink:contributes_to", "object": "MONDO:0005560", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6468526", "PMC:9027181", "PMC:6164814", "PMC:7235714", "PMC:8582389"], "tmkp_confidence_score": 0.8707724516700294, "sentences": "Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors|NA|Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors|NA|Pembrolizumab-induced encephalopathy: A review of neurological toxicities with immune checkpoint inhibitors|NA|Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors|NA|Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors|NA", "tmkp_ids": ["tmkp:1f3ff54cb37fbe090ece446529afb0dd5bc679023ca613b1d4a65c197eab454f", "tmkp:22c3843e456d96eedd6dd927e29e0a9ce8f8115b057c5a25d2ddaa56e15b79c2", "tmkp:4fcb95a77efad01b346f5afbde7ffa0af12f972cbc42598bc6414a352f24c951", "tmkp:b7deacfdd004d2f640f63b591ac687695ebc3a00fc7a58c18a437911c7ab82c7", "tmkp:dd0a0c1184439505778bbcf61a051ed2c308bf6d6d7966398950709e271872fa"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB09037", "original_object": "HP:0001298"}
{"subject": "UMLS:C0167117", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0001410", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7475780"], "tmkp_confidence_score": 1.165616253601696, "sentences": "Indeed, exenatide exerts hepato-protective as well as glucose-lowering actions combined with remarkable amelioration of anthropometric parameters and liver dysfunction markers.|NA", "tmkp_ids": ["tmkp:d504b32df3114d624069927929ac0cb52581fde4d5af0963cac59efa862f1afe"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB01276", "original_object": "HP:0001410"}
{"subject": "CHEBI:28115", "predicate": "biolink:subclass_of", "object": "CHEBI:75769", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:28115", "original_object": "CHEBI:75769"}
{"subject": "DRUGBANK:DB00028", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0032252", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:5709635"], "tmkp_confidence_score": 1.0259244902706532, "sentences": "This might explain the favorable response of our patient to IVIg monotherapy, since the pathologic findings showed a minimal amount of granuloma and mainly comprised follicular hyperplasia without a marked distortion of the parenchymal structures.|NA", "tmkp_ids": ["tmkp:60d569a0cd9b065a1c19221626ac58e1f3b97034c2fe1588d3796c289f2f7a1b"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB00028", "original_object": "HP:0032252"}
{"subject": "CHEBI:180472", "predicate": "biolink:subclass_of", "object": "CHEBI:17996", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:180472", "original_object": "CHEBI:23114"}
{"subject": "CHEBI:51700", "predicate": "biolink:subclass_of", "object": "HP:0000118", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:51700", "original_object": "HP:0000118"}
{"subject": "UMLS:C2826229", "predicate": "biolink:contributes_to", "object": "HP:0003326", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6601617"], "tmkp_confidence_score": 1.2497003426605344, "sentences": "Adverse events occurring more frequently in the ado-trastuzumab emtansine group than in the lapatinib plus capecitabine group included thrombo-cytopenia (31% vs 3%), constipation (27% vs 11%), increased amino transferase levels (29% vs 14%), headache (28% vs 15%), epistaxis (23% vs 8%), arthralgia (19% vs 8%), pyrexia (19% vs 8%), dry mouth (17% vs 5%), and myalgia (14% vs 4%).|NA", "tmkp_ids": ["tmkp:8fdf1c841e8c1bcd215311f8d96f2953f8e11c41f38a9d3dbbc763e3f572d21c"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB05773", "original_object": "HP:0003326"}
{"subject": "CHEBI:64220", "predicate": "biolink:contributes_to", "object": "MONDO:0007803", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:5291937"], "tmkp_confidence_score": 1.095903252151598, "sentences": "The in vivo neurotoxic effects of MSG are related to acute degenerative changes and chronic neurodegenerative defects, such as in vivo hypoglycemia, ischemia, trauma, multisystem atrophy, Huntington?s disease, and both dementia and amyotropic Alzheimer?s disease.|NA", "tmkp_ids": ["tmkp:62474bee324872cad414e07f86d4b4a12c48fd5948c90ea9af6afd75aeccf905"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "CHEBI:64220", "original_object": "MONDO:0007803"}
{"subject": "CHEBI:81777", "predicate": "biolink:subclass_of", "object": "CHEBI:60911", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:81777", "original_object": "CHEBI:60911"}
{"subject": "UniProtKB:P05231", "predicate": "biolink:affects", "object": "CHEBI:16336", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9227583", "PMC:9227583"], "tmkp_confidence_score": 0.99968174, "sentences": "Interestingly, the as-constructed SIM@HA-MSN exerts significantly stronger capability in attenuating the secretion of proinflammatory cytokines TNF-? and IL-6 and preventing the foaming of macrophages than free SIM and SIM@MSN, probably due to CD 44-mediated enhancements in cellular recognition and internalization.|NA|Strikingly, SIM@HA-MSN treatment led to the lowest level of TNF-? and IL-6 at 514.12 and 273.62 pg/mL, respectively, which were ~70% that of the SIM and SIM@MSN groups (Figure 4C).|NA", "tmkp_ids": ["tmkp:fdda9bb60efb6bc9fafc4c7d1de9945eeb2fe17fd4807db5aedb444b97702aba", "tmkp:12fa851d556098526b3b45b4f3c79195c3f888da8faa63b721a005f120c390e9"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "decreased", "original_subject": "UniProtKB:P05231", "original_object": "DRUGBANK:DB08818"}
{"subject": "UNII:76JZE5DSN6", "predicate": "biolink:contributes_to", "object": "HP:0002015", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9088458"], "tmkp_confidence_score": 0.99887985, "sentences": "An elderly female in her late 50s with a medical history of hypertension, developed acute onset facial puffiness, dysphagia, tongue, and neck swelling, with onset 1 week after the first dose of the BBV152 vaccine.|NA", "tmkp_ids": ["tmkp:51581b2716ebb0f9c05029fcc784614830f4e5f71331743f739e9cddec54b74b"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB15847", "original_object": "HP:0002015"}
{"subject": "CHEBI:145412", "predicate": "biolink:subclass_of", "object": "CHEBI:60004", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:4510", "original_object": "CHEBI:60004"}
{"subject": "CHEBI:132833", "predicate": "biolink:subclass_of", "object": "CHEBI:60911", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:132833", "original_object": "CHEBI:60911"}
{"subject": "UniProtKB:P22301", "predicate": "biolink:affects", "object": "UNII:O03S90U1F2", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMID:35372817", "PMC:8965165"], "tmkp_confidence_score": 0.9994282, "sentences": "In a dextran sulfate sodium-induced acute colitis murine model, LUT@TPGS-PBTE NPs alleviated body weight loss, colon length shortening, and damage to the colonic tissues due to the suppression of ROS and proinflammatory cytokines (e.g., IL-17A, IL-6, interferon-?, tumor necrosis factor-?), as well as upregulation of glutathione and anti-inflammatory factors (e.g., IL-10, IL-4).|NA|In a dextran sulfate sodium-induced acute colitis murine model, LUT@TPGS-PBTE NPs alleviated body weight loss, colon length shortening, and damage to the colonic tissues due to the suppression of ROS and proinflammatory cytokines (e.g., IL-17A, IL-6, interferon-?, tumor necrosis factor-?), as well as upregulation of glutathione and anti-inflammatory factors (e.g., IL-10, IL-4).|NA", "tmkp_ids": ["tmkp:b3fcc072720e4e910bf7e3aadcc00d90e08016365c874bdaae42f50ec95ca73b", "tmkp:cfa5f221e20364d0eb8838e5118603badb440a42a5603dc4263fa88fcc73321d"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "increased", "original_subject": "UniProtKB:P22301", "original_object": "DRUGBANK:DB11635"}
{"subject": "DRUGBANK:DB11003", "predicate": "biolink:contributes_to", "object": "MONDO:0008383", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6545587", "PMC:6545587", "PMC:6545587", "PMC:6545587"], "tmkp_confidence_score": 0.7443317808450571, "sentences": "Few cases of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) have been reported in persons who received AVA.|NA|Although our observations suggest that AVA might be a potential trigger for RA disease onset, additional studies would be needed, including assessing possible biological mechanisms, such as a specific autoimmune pathway that can be triggered by epitopes present in the vaccine, before this hypothesis could be confirmed.|NA|Anthrax Vaccine and the Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus in the U.S. Military: A Case?Control Study   |NA|AVA was associated with recent onset RA, but did not increase the risk of developing RA in the long term.|NA", "tmkp_ids": ["tmkp:4bb81dd295eeb4da99f763ee57a6fd578260d0e6ac6507e1968d241e41fe6997", "tmkp:822438515257cc93be62495c3688e4dd5a72f6dfca425a9f7bac8547cc5b5da2", "tmkp:ecefb820ee8982650ba28af19c60dbe5af86b59135b0e905c74849611020f846", "tmkp:1f5865e75d6b53ea4f5fb7fff3996413c38c7a5675c523a25f7d3ac62dcdd7ff"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB11003", "original_object": "MONDO:0008383"}
{"subject": "DRUGBANK:DB15656", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "MONDO:0009693", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8327056", "PMC:8553271", "PMC:8327056", "PMC:8327056", "PMC:8878129"], "tmkp_confidence_score": 0.99939111, "sentences": "To our knowledge, this is the first report to demonstrate the kinetics of NAbs-mediated humoral response in patients with MM after 2 doses of vaccination with the BNT162b2 vaccine and the first dose of AZD1222.|NA|A UK group studied IgG anti-spike protein antibodies in 93 patients with multiple myeloma (median age 65 years [range 47?87 years] in antibody-positive group and median age 70 years [47?87 years] in antibody-negative group) after one dose of either BNT162b2 or ChAdOx1 nCoV-19.|NA|In accordance to a previous study on healthy individuals, our results advocate for an earlier administration of the second dose of the AZD1222 especially for patients with MM.|NA|Vaccination with either two doses of the BNT162b2 or one dose of the AZD1222 vaccine leads to lower production of NAbs in patients with MM compared with controls both on day 22 and on day 50 (p?<?0.001 for all comparisons).|NA|Vaccination with either two doses of the BNT162b2 vaccine or one dose of the AZD1222 vaccine leads to lower production of NAbs in patients with MM compared with controls on days 22 and 50 (p < 0.001 for all comparisons).|NA", "tmkp_ids": ["tmkp:517831b89e1a94010f0f5eec2a60a4646add2f32f6ee9703d24b7f4c5f4182fe", "tmkp:27a3cb2f9c21d4ed8335134d7b1f9c76dadfec2113a2a1457f1f731229fb6e02", "tmkp:5ae2ed0c6b8cf7000972551e4b0676a53a9d5c30ba97411f53283f92214d9c98", "tmkp:37ff924524d01bdbb7ad0ae704547aac3f89289c65848dd453b46860ccbdf70d", "tmkp:aeec3526b6ec7b1de4a852471dba2a6364b02d52c674850089d99ac6fcce4679"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB15656", "original_object": "MONDO:0009693"}
{"subject": "MONDO:0018177", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "CHEBI:29033", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8962245"], "tmkp_confidence_score": 0.7072461795055985, "sentences": "Fe3O4-siPD-L1@M-BV2 significantly increased the accumulation of siPD-L1 and Fe2+ in orthotopic drug-resistant GBM tissue in mice.|NA", "tmkp_ids": ["tmkp:0873ef3adb44143f4cefd5d2035f236e16f10f5395d206fb0a9860f857908fac"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0018177", "original_object": "DRUGBANK:DB14510"}
{"subject": "MONDO:0005292", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "UNII:O03S90U1F2", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8965165", "PMC:8965165", "PMC:8965165"], "tmkp_confidence_score": 0.7781131668904292, "sentences": "LUT@TPGS-PBTE NPs rescued the hemoglobin of mice with colitis and showed no significant difference from the normal group.|NA|LUT@TPGS-PBTE NPs regulate CD4+ T lymphocyte subsets balance in colitis mice|NA|Besides, LUT@TPGS-PBTE NPs most effectively inhibited the percentage of Th17??cells (Fig.?7G?I) and suppress the levels of IL-17A protein and mRNA secreted by Th17 in the colitis mice.|NA", "tmkp_ids": ["tmkp:197bf2fb173cb264a2e292cd9338c7fa0f0892c5edf12c56a5c8ae77ec2a9ce8", "tmkp:bad4a4b273d30d8148caaeb143e5ec1a1fc927bd50e88480fcefc5c245359077", "tmkp:a7d4067d611fb4dde702b44581db88527ff5d0ff254161dbafd7ba91548fedb7"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0005292", "original_object": "DRUGBANK:DB11635"}
{"subject": "MONDO:0004992", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "CHEBI:31355", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6627870", "PMC:6627870", "PMC:6627870", "PMC:6627870", "PMC:7462495"], "tmkp_confidence_score": 0.26745989921726687, "sentences": "The obtained results give insights into the potential of PAMAM G3.0@mPEG dendrimer as an efficient delivery system for the delivery of a drug that has strong side effects and fast renal clearance like CAR, which could be a promising approach for cancer treatment.|NA|These obtained results provide insights into the potential of PAMAM G3.0@mPEG dendrimer as an efficient delivery system for the delivery of a drug that has strong side effects and fast renal clearance like CAR, which could be a promising approach for cancer treatment.|NA|Taken together, these results indicated that CAR/PAMAM G3.0@mPEG could fully retain the bioactivity of released CAR to suppress the proliferation of various types of cancer cells.|NA|Notably, an in vitro release test and cell viability assays against HeLa, A549, and MCF7 cell lines indicated that CAR/PAMAM G3.0@mPEG could provide a sustained release of CAR while fully retaining its bioactivity to suppress the proliferation of cancer cells.|NA|Davarpanah et al. (2019) also used Fe3O4@SiO2 NPs for targeted delivery of Carboplatin to the cancer cells.|NA", "tmkp_ids": ["tmkp:583904dfd393b0add57a01ffdb61fff63208b28bc853311c7222efa393e4fc41", "tmkp:df5fbc0e1c34d21691ee7ab3f9e52621a3d5c8ed6b8b76b946ff7521cb46f39a", "tmkp:24f4f89b5e200b0ccc7d0693c37555a0d07c7ed0ef83404387a6b3f202fc5af2", "tmkp:e86211b0e51ce463484e7f0d84fa36c2ebbd3a9f7e67fad1829043b3cdecea6f", "tmkp:0c1c72dc62ea2204287facf86c2cf99f8940455a22fac52ff43e682bc1338630"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0004992", "original_object": "DRUGBANK:DB00958"}
{"subject": "DRUGBANK:DB15656", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "HP:0005305", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9145068", "PMC:9198750"], "tmkp_confidence_score": 0.99936695, "sentences": "In agreement with the well-known relationship between the ChAdOx1 nCoV-19 vaccine and CVT, our results showed a potential safety signal of the ChAdOx1 nCoV-19 vaccine for CVT.|NA|In this self-controlled case series, there was an increased rate of hospital contacts because of coagulation disorders and cerebrovascular disease, especially for thrombocytopenia and cerebral venous thrombosis, following vaccination with AZD1222.|NA", "tmkp_ids": ["tmkp:f0d905f089d3895a6c5823ce2574af431c99ca34366c24b0a515895ce98b8b06", "tmkp:16d23e37a004a874c0d2972f62834c8b0a49a268d087452c1def21cba195def1"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB15656", "original_object": "HP:0005305"}
{"subject": "DRUGBANK:DB15656", "predicate": "biolink:affects", "object": "UniProtKB:Q9BYF1", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8810924", "PMC:9349502", "PMC:8322137", "PMC:8810924", "PMC:9349502"], "tmkp_confidence_score": 0.999701372, "sentences": "Therefore, given that the ACE2 receptor blocking antibody levels were significantly lower than following a single dose of AZD1222 and since the proportion of individuals who developed ACE2 receptor blocking antibodies were also significantly lower, especially in the older age groups.|NA|A direct comparison between four different vaccines showed that 2 to 3?months post immunization showed that the Pfizer?BioNTech (BNT162b2), elicited the highest levels of ACE2 blocking antibodies, followed by AZD1222, Sputnik V and Sinopharm.|NA|However, a single dose of the AZD1222 vaccine in previously exposed individuals not only significantly increased their ACE2-blocking antibodies but also significantly increased the RBD antibodies for the variants such the B.1.1.7 and B.1.351.|NA|Therefore, given that the ACE2 receptor blocking antibody levels were significantly lower than following a single dose of AZD1222 and since the proportion of individuals who developed ACE2 receptor blocking antibodies were also significantly lower, especially in the older age groups.|NA|The ACE2 blocking antibody levels were also significantly higher (P?<?0.0001) in those who received Moderna compared to those who received AZD1222 (Figure?2d).|NA", "tmkp_ids": ["tmkp:451679b72eae7f9ff97a6197ddde92e2f56f4a3dfd035cfc16d1bdd05145a17c", "tmkp:1b5b360245acdf0e177ffcdf89762256cf37466c28bd093930bba5f6e2f18725", "tmkp:392c5534a692fec2d26ac44d4d27af2d7e52ac99ee9499dd7eeab0391963af01", "tmkp:ae23e48673e8666bcf3a82e7245b381fc546699fe92a254b6366b9f0b07bc345", "tmkp:a5a4b8a42837e1ff9db086698f92fdc29d8bea787effeb091637354fd46f24eb"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "decreased", "original_subject": "DRUGBANK:DB15656", "original_object": "UniProtKB:Q9BYF1"}
{"subject": "MONDO:0002492", "predicate": "biolink:contributes_to", "object": "CHEBI:27470", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7760472"], "tmkp_confidence_score": 0.9054703295277998, "sentences": "AKI mice were intravenously administered with siP53@L-sTd at 2 and 24 h after injection of folic acid to induce AKI and sacrificed after an additional 24 h to investigate the therapeutic efficacy of the siRNA (0.25 mg/kg per injection) (Figure 3e).|NA", "tmkp_ids": ["tmkp:1c91a32dfa498b8081a25cf35338963ffe4d7ef84fc1cd84e571513d6eb9d8b9", "tmkp:1d3a46604cd8ebfc54f9b58f2493cce6312452cf94aa165e728b1c43e4aabb3e"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0002492", "original_object": "CHEBI:27470"}
{"subject": "MONDO:0005004", "predicate": "biolink:subclass_of", "object": "UMLS:C1518174", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "NCIT:C36815", "original_object": "NCIT:C36779"}
{"subject": "CHEBI:39362", "predicate": "biolink:subclass_of", "object": "CHEBI:25562", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:39362", "original_object": "CHEBI:25562"}
{"subject": "MONDO:0005311", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "UMLS:C0020197", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9227583", "PMC:9227583"], "tmkp_confidence_score": 0.657340224460825, "sentences": "Herein, we constructed an enzyme-responsive and macrophage-targeting drug delivery system (SIM@HA-MSN) which can potentially modulate the microenvironment of the atherosclerotic plaques characterized by excessive inflammation and overexpression of hyaluronidase (HAase) for precise AS treatment.|NA|Herein, we constructed an enzyme-responsive and macrophage-targeting drug delivery system (SIM@HA-MSN) which can potentially modulate the microenvironment of the atherosclerotic plaques characterized by excessive inflammation and overexpression of hyaluronidase (HAase) for precise AS treatment.|NA", "tmkp_ids": ["tmkp:f2dc22edcee0944b909bc81fd441c68bce625437b524fb0e728764b5a9be667b", "tmkp:a26f36302fc9df705ce094b31aff04797c0a4783d1fc2d9f59adaef72ec92c75"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0005311", "original_object": "DRUGBANK:DB14740"}
{"subject": "CHEBI:34762", "predicate": "biolink:subclass_of", "object": "CHEBI:60004", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:34762", "original_object": "CHEBI:60004"}
{"subject": "MONDO:0021156", "predicate": "biolink:subclass_of", "object": "UBERON:0001062", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "NCIT:C12399", "original_object": "NCIT:C12219"}
{"subject": "DRUGBANK:DB15656", "predicate": "biolink:contributes_to", "object": "HP:0002829", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8343389", "PMC:9085349", "PMC:8493039"], "tmkp_confidence_score": 0.99221243, "sentences": "Systemic side effects such as fever (56.3% vs. 13.3%, p?=?0.001), chills (37.5% vs. 6.7%, p?=?0.001), myalgia (50% vs. 40%, p?=?0.001), and arthralgia (25% vs. 6.7%, p?=?0.021) were statistically significantly higher after the first dose of ChAdOx1nCoV-19 vaccine than after the first dose of BBNT162b2 vaccine.|NA|The phase 2?3 trial of the AZD1222 vaccine reported systemic adverse effects such as headache (22.8%), fatigue (21.1%), arthralgia (11.5%), chills, and shivering (14.7%) in 88% of participants aged 18?55 years who received the first injection.|NA|The reactogenicity scores for pain, fever, chill, myalgia, arthralgia, fatigue, headache, and AAP requirement were significantly higher in the ChAd group compared to the BNT group (all P < 0.05).|NA", "tmkp_ids": ["tmkp:d1f9e32ed38ab6c71ccf9c00f3e16afd80d555c7d20e48f548adacf4525f8ce9", "tmkp:6f369aa736b30fc5c3a53aeac6b1cf2d04a4f432fe5f58d892ae33478fe8de59", "tmkp:0733d29def3907181568e664e2f4e35a5a220aa077c133e100363f1dd768da97"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "DRUGBANK:DB15656", "original_object": "HP:0002829"}
{"subject": "UniProtKB:P01579", "predicate": "biolink:affects", "object": "CHEBI:31941", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8280231"], "tmkp_confidence_score": 0.9990939, "sentences": "Oxa(IV)@ZnPc (+) and Oxa(IV)@ZnPc@M (+) groups had higher serum concentration of IFN-? and TNF-? than the PBS (+) group and the non-laser group, indicating that PDT could induce acute inflammatory response.|NA", "tmkp_ids": ["tmkp:3e2171072abb1389b5ff9097fc572231af58ee80a28ba26ab27c8c40d5c3d333"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "qualified_predicate": "biolink:causes", "object_aspect_qualifier": "activity_or_abundance", "object_direction_qualifier": "increased", "original_subject": "UniProtKB:P01579", "original_object": "DRUGBANK:DB00526"}
{"subject": "CHEBI:68837", "predicate": "biolink:subclass_of", "object": "CHEBI:25741", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:68837", "original_object": "CHEBI:25741"}
{"subject": "HP:4000055", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "CHEBI:3962", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8612690"], "tmkp_confidence_score": 0.9986552, "sentences": "SP@Curcumin-mediated anti-inflammatory effects against intestinal inflammation.|NA", "tmkp_ids": ["tmkp:24b2f501a43123812c5808783ca6e292afe5e41b9dc16aaf14252e24238b51b6"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "HP:4000055", "original_object": "DRUGBANK:DB11672"}
{"subject": "MONDO:0004934", "predicate": "biolink:subclass_of", "object": "UBERON:0002384", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "NCIT:C13184", "original_object": "NCIT:C12374"}
{"subject": "UMLS:C1711306", "predicate": "biolink:subclass_of", "object": "MONDO:0005004", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "NCIT:C47821", "original_object": "NCIT:C36815"}
{"subject": "CHEBI:190303", "predicate": "biolink:subclass_of", "object": "HP:0000118", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:190303", "original_object": "HP:0000118"}
{"subject": "CHEBI:4067", "predicate": "biolink:subclass_of", "object": "PR:000000001", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:4067", "original_object": "PR:000000001"}
{"subject": "MONDO:0007256", "predicate": "biolink:contributes_to", "object": "CHEBI:50845", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8964448"], "tmkp_confidence_score": 0.6378220604284649, "sentences": "The tissue distribution and chemo- and photodynamic therapeutic effects of HCPT@NMOFs-RGD were evaluated in a doxycycline-induced zebrafish HCC model and xenograft mouse model.|NA", "tmkp_ids": ["tmkp:0551db48f45be7647d28a8fd97e9682c415dad43d1b5a84ad8d8eb3f03af3596", "tmkp:901093f33ce3fcd2f971b24332b789e882a573014b51adc9545625b02ca0b2a3"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0007256", "original_object": "DRUGBANK:DB00254"}
{"subject": "HP:0001945", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "UniProtKB:P02768", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:7755349"], "tmkp_confidence_score": 0.6184915950211146, "sentences": "Treatment using SPIO@PSS/CDDP/HSA?MTX NPs and RF irradiation allows the CDDP-based chemotherapeutic drug to act synergistically with hyperthermia to provide a profound anticancer effect.|NA", "tmkp_ids": ["tmkp:b2acb3d5f7152b54b1f9fd2acb37195233305b3ec8bc7ec46beef89fa0680ca0"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "HP:0001945", "original_object": "DRUGBANK:DB00062"}
{"subject": "UBERON:0012281", "predicate": "biolink:subclass_of", "object": "MONDO:0002260", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "NCIT:C77610", "original_object": "NCIT:C32132"}
{"subject": "CHEBI:32293", "predicate": "biolink:subclass_of", "object": "CHEBI:60004", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:32293", "original_object": "CHEBI:60004"}
{"subject": "HP:0100282", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "UNII:O03S90U1F2", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:8965165"], "tmkp_confidence_score": 0.99895835, "sentences": "Antioxidant and anti-inflammatory effects of DiR@TPGS-PBTE NPs on acute colitis in mice.|NA", "tmkp_ids": ["tmkp:32c2246be18b5900bef01d1a60d5993e8806621a8217cbbeafe2868e7d40be20"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "HP:0100282", "original_object": "DRUGBANK:DB11635"}
{"subject": "CHEBI:17089", "predicate": "biolink:subclass_of", "object": "PR:000000001", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:17089", "original_object": "PR:000000001"}
{"subject": "MONDO:0002771", "predicate": "biolink:contributes_to", "object": "UMLS:C0005740", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:9216512", "PMC:9216512", "PMC:9216512"], "tmkp_confidence_score": 0.7726991358851115, "sentences": "siIL11@PPGC NPs mitigate bleomycin-induced pulmonary fibrosis|NA|Inhalation of siIL11@PPGC NPs restores the pulmonary function in the mouse model of bleomycin-induced pulmonary fibrosis.|NA|Inhaled siIL11@PPGC NPs inhibit fibroblast activation and ECM production in the mouse model of bleomycin-induced pulmonary fibrosis.|NA", "tmkp_ids": ["tmkp:b8912185ebff2fc55c48ddd3bb91b32312272f256b3ba3087342582974ebfea4", "tmkp:78d960c43593a81792c361d16f360bdb8fc50a085c3297351f7e2d72675045ed", "tmkp:853d0a215b0f9905a36e383fdb2b8005b51c7230fe3741bc0b47a75e5d27c143"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "MONDO:0002771", "original_object": "DRUGBANK:DB00290"}
{"subject": "HP:0001945", "predicate": "biolink:treats_or_applied_or_studied_to_treat", "object": "CHEBI:184335", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6857040"], "tmkp_confidence_score": 0.8347018459598716, "sentences": "Overall, the good stability of DOX-DiR@cerasome (ABC), together with its rapidly accelerated drug release under hyperthermia, made it possible for effective anticancer drug delivery with reduced undesirable premature leakage and on-demand site specific release, thus enhancing chemo-photothermal combination therapy.|NA", "tmkp_ids": ["tmkp:867e621b6100eeb3be07028f3fc18e1bf793b914f4815f7e8ff8900748e1dee7"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "HP:0001945", "original_object": "DRUGBANK:DB15925"}
{"subject": "CHEBI:29103", "predicate": "biolink:subclass_of", "object": "HP:0000118", "primary_knowledge_source": "infores:ubergraph", "knowledge_level": "knowledge_assertion", "agent_type": "manual_agent", "original_subject": "CHEBI:29103", "original_object": "HP:0000118"}
{"subject": "HP:0001510", "predicate": "biolink:contributes_to", "object": "CHEBI:27899", "primary_knowledge_source": "infores:text-mining-provider-targeted", "publications": ["PMC:6376191"], "tmkp_confidence_score": 0.6529963641100585, "sentences": "As shown in Figure 9C-D and Figure S18A, C, HT@CDDP induced a remarkable tumor growth delay and, 13 days after treatment, the tumor size (5.70 ? 1.14 mm3) was reduced by 82.78% compared with the untreated control (33.11 ? 4.63 mm3).|NA", "tmkp_ids": ["tmkp:13577809435a7de92b00b14fc5a14ff8c010a136e900860b78ae02928a9088ea"], "knowledge_level": "not_provided", "agent_type": "text_mining_agent", "original_subject": "HP:0001510", "original_object": "DRUGBANK:DB00515"}